康复新液联合埃索美拉唑在慢性胃炎Hp感染中的应用

Application of Kangfuxin Liquid Combined with Esomeprazole in the Treatment of Hp Infection in Chronic Gastritis

目的探讨康复新液与埃索美拉唑四联疗法在慢性胃炎幽门螺杆菌(helicobacter pylori,HP)感染中的应用及对胃泌素的影响。方法选择2019年4月至2020年3月菏泽市第二人民医院收治的慢性胃炎HP感染患者128例随机数字表法划分为两组。对照组64例采用埃索美拉唑为主的四联疗法治疗,研究组64例在此基础上联合康复新液治疗。比较两组临床疗效、治疗前后胃泌素族[胃泌素(gastrin,GAS)、胃动素(motilin,MTL)]、白细胞介素-17(interleukin-17,IL-17)与转化生长因子-β(transforming growth factorβ1,TGF-β1)水平,以及不良反应情况。结果研究组治疗的总有效率为96.88%,高于对照组的85.94%,差异有统计学意义(P<0.05)。研究组Hp清除率为98.44%,高于对照组的87.50%(P<0.05)。治疗后,研究组GAS、MTL水平低于对照组(P<0.01)。治疗后,研究组IL-17、TGF-β1水平低于对照组(P<0.01)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论慢性胃炎Hp感染患者应用康复新液与埃索美拉唑四联疗法治疗可以取得满意的效果,且改善了胃泌素指标,适于临床推广。

Objective To explore the application of Kangfuxin Liquid and esomeprazole quadruple therapy in helicobacter pylori(HP)infection of chronic gastritis and its effect on gastrin.Methods A total of 128 patients with chronic gastritis Hp infection treated in Second People’s Hospital of Heze City from April 2019 to March 2020 were randomly divided into two groups.64 cases in the control group were treated with esomeprazole based quadruple therapy,and 64 cases in the study group were treated with Kangfuxin Liquid.The clinical efficacy,gastrin family[gastrin(gas),motilin(MTL)],interleukin-17(IL-17)and transforming growth factor after and before treatment between two groups TGF-β(TGF-β1)level and adverse reactions.Results The total effective rate of the stydy groupwas 96.88%,which was higher than the control group 54.69%.The Hp clearance rate of the study group was 98.44%,which was higher than control group 87.50%(P<0.05).The levels of MTL gas after treatment in the study group were lower than those in the control group(P<0.01).The level of IL-1 was lower than the control group(P<0.01).Adverse reaction comparison,no difference in the two groups(P>0.05).Conclusion The application of Kangfuxin liquid and esomeprazole quadruple therapy in patients with chronic gastritis HP infection can achieve satisfactory results,and improve the gastrin index.